Vertex announces reimbursement agreement in australia for trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for patients with cystic fibrosis ages 12 years and older with at least one f508del mutation in the cftr gene

London--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that as of 1 april 2022, trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) will be reimbursed on the australian pharmaceutical benefits scheme (pbs) for the treatment of cystic fibrosis (cf) in people ages 12 years and older who have at least one f508del mutation in the cftr gene, the most common cf-causing mutation worldwide. “today's announcement is a significant milestone in ensuring australi
VRTX Ratings Summary
VRTX Quant Ranking